Breaking News

Single-dose Peginterferon Significantly Reduced COVID-19 Hospitalization or ER Risk

March 17, 2022 • 3:03 pm CDT
Image by Sammy-Sander
(Precision Vaccinations News)

California-based Eiger BioPharmaceuticals, Inc. today announced that Peginterferon Lambda was found to significantly reduce the risk of COVID-19-related hospitalizations or emergency room visits greater than six hours by 50% and death by 60% in the Phase 3 TOGETHER study.

Lambda is a late-stage, first-in-class, type III interferon that stimulates immune responses critical to innate defenses with a mechanism of action potentially agnostic to variants of the SARS-CoV-2 coronavirus and resistance concerns with other treatments. 

The final analyses evaluated data from 1,936 patients, with 84% of patients receiving at least a single dose of any COVID-19 vaccine.

Eiger plans to discuss the results with U.S. FDA and submit an authorization request as soon as possible.

"These data demonstrate that a single subcutaneous injection of Lambda has the potential to be a convenient, 'one and done' treatment to reduce the severity of COVID-19, reducing hospitalizations and death, even in a vaccinated population," said Eiger President and CEO, David Cory, in a related press release issued on March 17, 2022.

The Phase 3 TOGETHER study of Lambda is the second largest study of a COVID-19 therapeutic.

Lambda has been administered to over 3,000 subjects in 23 clinical trials focused on hepatitis and COVID-19. And Eiger has received Orphan Designation from the U.S. FDA and European Medicines Agency.

However, Lambda is an investigational agent and has not yet been approved for any indication. 

Additional COVID-19 treatment news is posted at PrecisionVaccinations.com/antivirals.

Note: This press release was edited for clarity and curated for mobile readers.

Our Trust Standards: Medical Advisory Committee

Share